xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06025383</url>
    </required_header>
    <id_info>
      <org_study_id>IRB2022-1055</org_study_id>
      <nct_id>NCT06025383</nct_id>
    </id_info>
    <brief_title>2 Weeks of Citrulline Supplementation on Arterial Function in Postmenopausal Women With Elevated Blood Pressure or Hypertension</brief_title>
    <official_title>2 Weeks of L-Citrulline Supplementation Improves Arterial Function and Systolic Blood Pressure at Rest and During Exercise in Postmenopausal Women With Elevated Blood Pressure and Hypertension</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Texas Tech University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Texas Tech University</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The objective of this project is to elucidate the effect of L-Citrulline (L-CIT)&#xD;
        supplementation on vascular function at rest and during rhythmic handgrip exercise and&#xD;
        functional sympatholysis via lower-body negative pressure in postmenopausal women with&#xD;
        elevated blood pressure and hypertension.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Using a double-blind, randomized, placebo-controlled, and crossover design, overweight or&#xD;
        obese postmenopausal women with elevated blood pressure (BP) or hypertension will receive CIT&#xD;
        (6 grams/day) or placebo for 2 weeks, separated by a two-week washout period.&#xD;
  &#xD;
        There will be a total of 5 laboratory visits. The 1st visit will take approximately 1 hour.&#xD;
        The 2nd - 5th visits will take about 2 hours and 15 minutes. Visit 1 will be a screening&#xD;
        visit, visits 2 and 4 will be considered baseline visits, and visits 3 and 5 will be&#xD;
        following the participants' two weeks of supplementation. Arterial stiffness (carotid-femoral&#xD;
        and femoral-dorsalis pedis pulse wave velocity) and endothelial function will be assessed at&#xD;
        rest. Additionally, brachial artery blood flow, forearm muscle oxygenation, cardiovascular&#xD;
        hemodynamics (stroke volume, cardiac output, systemic vascular resistance), and BP will be&#xD;
        assessed at rest, during 6 minutes of rhythmic handgrip exercise at 30% of a predetermined&#xD;
        maximal voluntary contraction, and 2 minutes of superimposed lower body negative pressure to&#xD;
        increase sympathetic activity.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">July 20, 2023</start_date>
    <completion_date type="Anticipated">July 2024</completion_date>
    <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Crossover Assignment</intervention_model>
      <intervention_model_description>Cross-Over Assignment Double (Participant, Investigator) randomized, double-blind, placebo-controlled, cross-over study design</intervention_model_description>
      <primary_purpose>Basic Science</primary_purpose>
      <masking>Double (Participant, Investigator)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Macrovascular endothelial function at rest</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Endothelial function will be assessed via brachial artery flow-mediated vasodilation (ultrasonography) during reactive hyperemia at baseline and after 2 weeks of each supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Microvascular endothelial function at rest</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Endothelial function will be assessed via peripheral arterial tonometry (endoPAT) during reactive hyperemia at baseline and after 2 weeks of each supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Microvascular endothelial function at rest</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Endothelial function will be assessed using forearm muscle oxygen saturation (near-infrared spectroscopy) during reactive hyperemia before and after 2 weeks of each supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Brachial artery blood flow at rest and during rhythmic handgrip exercise with and without lower-body negative pressure</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Blood flow will be measured via Doppler ultrasound before and after 2 weeks of each intervention.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Forearm muscle oxygenation at rest and during rhythmic handgrip exercise with and without lower-body negative pressure</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Muscle oxygen saturation will be measured via near-infrared spectroscopy before and after 2 weeks of each intervention.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Beat-to-beat blood pressure at rest and during rhythmic handgrip exercise with and without lower-body negative pressure</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Blood pressure will be measured via a finger cuff (finometer) before and after 2 weeks of each intervention.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Aortic hemodynamics at rest and during rhythmic handgrip exercise with and without lower body negative pressure</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Aortic blood pressure and pressure waves will be assessed using radial applanation tonometry before and after 2 weeks of each intervention.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Stroke volume at rest and during rhythmic handgrip exercise with and without lower body negative pressure</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Stroke volume will be assessed via impedance cardiography before and after 2 weeks of each intervention.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Heart rate at rest and during rhythmic handgrip exercise with and without lower body negative pressure</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Heart rate will be assessed via impedance cardiography before and after 2 weeks of each intervention.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Systemic vascular resistance at rest and during rhythmic handgrip exercise with and without lower body negative pressure</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Systemic vascular resistance will be assessed via impedance cardiography before and after 2 weeks of each intervention.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Central and peripheral arterial stiffness at rest</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Carotid-femoral and femoral-dorsalis pedis pulse wave velocity will be measured using arterial applanation tonometry before and after 2 weeks of each intervention.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Forearm muscle strength</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Maximal forearm muscle strength will be measured using a handgrip dynamometer before and after 2 weeks of each intervention.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>L-arginine levels</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Serum levels of l-arginine will be assessed before and after 2 weeks of each intervention.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Nitric oxide levels</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Serum levels of nitric oxide will be assessed before and after 2 weeks of each intervention.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>L-citrulline levels</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Serum levels of l-citrulline will be assessed before and after 2 weeks of each intervention.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>L-ornithine levels</measure>
      <time_frame>2 weeks of each intervention</time_frame>
      <description>Serum levels of l-ornithine will be assessed before and after 2 weeks of each intervention.</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">19</enrollment>
    <condition>Menopause</condition>
    <condition>Hypertension</condition>
    <arm_group>
      <arm_group_label>L-Citrulline</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>L-Citrulline: 6 grams/day divided in 2 equal doses</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Placebo</arm_group_label>
      <arm_group_type>Placebo Comparator</arm_group_type>
      <description>Microcrystalline cellulose: 8 capsules/day divided into 2 equal doses</description>
    </arm_group>
    <intervention>
      <intervention_type>Dietary Supplement</intervention_type>
      <intervention_name>L-Citrulline</intervention_name>
      <description>2 weeks of L-Citrulline supplementation (6 grams/day)</description>
      <arm_group_label>L-Citrulline</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Dietary Supplement</intervention_type>
      <intervention_name>Placebo</intervention_name>
      <description>2 weeks of microcrystalline cellulose supplementation (8 capsules/day)</description>
      <arm_group_label>Placebo</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Postmenopausal women (defined as the absence of menstruation for at least 1 year).&#xD;
  &#xD;
            -  Resting systolic blood pressure 120-150 mmHg.&#xD;
  &#xD;
            -  Between the ages of 50 - 70 years.&#xD;
  &#xD;
            -  Sedentary (&lt; 120 minutes of exercise/week).&#xD;
  &#xD;
            -  Body mass index of 25 - 39.9 kg/m2.&#xD;
  &#xD;
            -  Fasting glucose &lt; 126 mg/dL and HbA1c &lt; 6.5%.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Body mass index ≥ 40 or &lt; 25 kg/m2.&#xD;
  &#xD;
            -  Systolic blood pressure &gt; 150 mmHg.&#xD;
  &#xD;
            -  Taking more than two antihypertensive medications.&#xD;
  &#xD;
            -  Cardiovascular diseases, type I/II diabetes, musculoskeletal disorders, or cancer.&#xD;
  &#xD;
            -  Changes in hypertensive medication in the past three months.&#xD;
  &#xD;
            -  Began or changed hormone replacement therapy in the past 6 months.&#xD;
  &#xD;
            -  Current smoker.&#xD;
  &#xD;
            -  Heavy drinking (&gt; 7 alcoholic drinks/week).&#xD;
  &#xD;
            -  Participants on beta-blockers or other vasodilatory supplements (nitrates).&#xD;
  &#xD;
            -  Incorporated in a weight loss program and/or aerobic or resistance training program.&#xD;
        </textblock>
      </criteria>
      <gender>Female</gender>
      <minimum_age>50 Years</minimum_age>
      <maximum_age>70 Years</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Arturo Figueroa</last_name>
      <role>Principal Investigator</role>
      <affiliation>Texas Tech University</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Arturo Figueroa</last_name>
      <phone>806-834-5587</phone>
      <email>Arturo.Figueroa@ttu.edu</email>
    </overall_contact>
    <location>
      <facility>
        <name>Texas Tech University</name>
        <address>
          <city>Lubbock</city>
          <state>Texas</state>
          <zip>79409</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Donna Torres</last_name>
        <phone>806-834-6935</phone>
        <email>Donna.Torres@ttu.edu</email>
      </contact>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <reference>
      <citation>Maharaj A, Fischer SM, Dillon KN, Kang Y, Martinez MA, Figueroa A. Acute Citrulline Blunts Aortic Systolic Pressure during Exercise and Sympathoactivation in Hypertensive Postmenopausal Women. Med Sci Sports Exerc. 2022 May 1;54(5):761-768. doi: 10.1249/MSS.0000000000002848. Epub 2022 Jan 3.</citation>
      <PMID>34974502</PMID>
    </reference>
    <reference>
      <citation>Maharaj A, Fischer SM, Dillon KN, Kang Y, Martinez MA, Figueroa A. Effects of L-Citrulline Supplementation on Endothelial Function and Blood Pressure in Hypertensive Postmenopausal Women. Nutrients. 2022 Oct 20;14(20):4396. doi: 10.3390/nu14204396.</citation>
      <PMID>36297080</PMID>
    </reference>
    <reference>
      <citation>Kang Y, Dillon KN, Martinez MA, Maharaj A, Fischer SM, Figueroa A. Combined L-Citrulline Supplementation and Slow Velocity Low-Intensity Resistance Training Improves Leg Endothelial Function, Lean Mass, and Strength in Hypertensive Postmenopausal Women. Nutrients. 2022 Dec 23;15(1):74. doi: 10.3390/nu15010074.</citation>
      <PMID>36615732</PMID>
    </reference>
    <reference>
      <citation>Figueroa A, Maharaj A, Kang Y, Dillon KN, Martinez MA, Morita M, Nogimura D, Fischer SM. Combined Citrulline and Glutathione Supplementation Improves Endothelial Function and Blood Pressure Reactivity in Postmenopausal Women. Nutrients. 2023 Mar 23;15(7):1557. doi: 10.3390/nu15071557.</citation>
      <PMID>37049398</PMID>
    </reference>
    <reference>
      <citation>Figueroa A, Alvarez-Alvarado S, Jaime SJ, Kalfon R. l-Citrulline supplementation attenuates blood pressure, wave reflection and arterial stiffness responses to metaboreflex and cold stress in overweight men. Br J Nutr. 2016 Jul;116(2):279-85. doi: 10.1017/S0007114516001811. Epub 2016 May 10.</citation>
      <PMID>27160957</PMID>
    </reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 19, 2023</study_first_submitted>
    <study_first_submitted_qc>August 29, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 6, 2023</study_first_posted>
    <last_update_submitted>August 29, 2023</last_update_submitted>
    <last_update_submitted_qc>August 29, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 6, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Texas Tech University</investigator_affiliation>
      <investigator_full_name>Arturo Figueroa</investigator_full_name>
      <investigator_title>Arturo Figueroa, Principal Investigator</investigator_title>
    </responsible_party>
    <keyword>Endothelial function</keyword>
    <keyword>Blood flow</keyword>
    <keyword>Blood pressure</keyword>
    <keyword>Functional sympatholysis</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Hypertension</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06025383
  org study id: IRB2022-1055
  nct id: NCT06025383
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  The objective of this project is to elucidate the effect of L-Citrulline (L-CIT)
        supplementation on vascular function at rest and during rhythmic handgrip exercise and
        functional sympatholysis via lower-body negative pressure in postmenopausal women with
        elevated blood pressure and hypertension.
  Using a double-blind, randomized, placebo-controlled, and crossover design, overweight or
        obese postmenopausal women with elevated blood pressure (BP) or hypertension will receive CIT
        (6 grams/day) or placebo for 2 weeks, separated by a two-week washout period.
  
        There will be a total of 5 laboratory visits. The 1st visit will take approximately 1 hour.
        The 2nd - 5th visits will take about 2 hours and 15 minutes. Visit 1 will be a screening
        visit, visits 2 and 4 will be considered baseline visits, and visits 3 and 5 will be
        following the participants' two weeks of supplementation. Arterial stiffness (carotid-femoral
        and femoral-dorsalis pedis pulse wave velocity) and endothelial function will be assessed at
        rest. Additionally, brachial artery blood flow, forearm muscle oxygenation, cardiovascular
        hemodynamics (stroke volume, cardiac output, systemic vascular resistance), and BP will be
        assessed at rest, during 6 minutes of rhythmic handgrip exercise at 30% of a predetermined
        maximal voluntary contraction, and 2 minutes of superimposed lower body negative pressure to
        increase sympathetic activity.
  allocation: Randomized
  intervention model: Crossover Assignment
  intervention model description: Cross-Over Assignment Double (Participant, Investigator) randomized, double-blind, placebo-controlled, cross-over study design
  primary purpose: Basic Science
  masking: Double (Participant, Investigator)
  measure: Macrovascular endothelial function at rest
  time frame: 2 weeks of each intervention
  description: Endothelial function will be assessed via brachial artery flow-mediated vasodilation (ultrasonography) during reactive hyperemia at baseline and after 2 weeks of each supplementation.
  measure: Microvascular endothelial function at rest
  time frame: 2 weeks of each intervention
  description: Endothelial function will be assessed via peripheral arterial tonometry (endoPAT) during reactive hyperemia at baseline and after 2 weeks of each supplementation.
  measure: Microvascular endothelial function at rest
  time frame: 2 weeks of each intervention
  description: Endothelial function will be assessed using forearm muscle oxygen saturation (near-infrared spectroscopy) during reactive hyperemia before and after 2 weeks of each supplementation.
  measure: Brachial artery blood flow at rest and during rhythmic handgrip exercise with and without lower-body negative pressure
  time frame: 2 weeks of each intervention
  description: Blood flow will be measured via Doppler ultrasound before and after 2 weeks of each intervention.
  measure: Forearm muscle oxygenation at rest and during rhythmic handgrip exercise with and without lower-body negative pressure
  time frame: 2 weeks of each intervention
  description: Muscle oxygen saturation will be measured via near-infrared spectroscopy before and after 2 weeks of each intervention.
  measure: Beat-to-beat blood pressure at rest and during rhythmic handgrip exercise with and without lower-body negative pressure
  time frame: 2 weeks of each intervention
  description: Blood pressure will be measured via a finger cuff (finometer) before and after 2 weeks of each intervention.
  measure: Aortic hemodynamics at rest and during rhythmic handgrip exercise with and without lower body negative pressure
  time frame: 2 weeks of each intervention
  description: Aortic blood pressure and pressure waves will be assessed using radial applanation tonometry before and after 2 weeks of each intervention.
  measure: Stroke volume at rest and during rhythmic handgrip exercise with and without lower body negative pressure
  time frame: 2 weeks of each intervention
  description: Stroke volume will be assessed via impedance cardiography before and after 2 weeks of each intervention.
  measure: Heart rate at rest and during rhythmic handgrip exercise with and without lower body negative pressure
  time frame: 2 weeks of each intervention
  description: Heart rate will be assessed via impedance cardiography before and after 2 weeks of each intervention.
  measure: Systemic vascular resistance at rest and during rhythmic handgrip exercise with and without lower body negative pressure
  time frame: 2 weeks of each intervention
  description: Systemic vascular resistance will be assessed via impedance cardiography before and after 2 weeks of each intervention.
  measure: Central and peripheral arterial stiffness at rest
  time frame: 2 weeks of each intervention
  description: Carotid-femoral and femoral-dorsalis pedis pulse wave velocity will be measured using arterial applanation tonometry before and after 2 weeks of each intervention.
  measure: Forearm muscle strength
  time frame: 2 weeks of each intervention
  description: Maximal forearm muscle strength will be measured using a handgrip dynamometer before and after 2 weeks of each intervention.
  measure: L-arginine levels
  time frame: 2 weeks of each intervention
  description: Serum levels of l-arginine will be assessed before and after 2 weeks of each intervention.
  measure: Nitric oxide levels
  time frame: 2 weeks of each intervention
  description: Serum levels of nitric oxide will be assessed before and after 2 weeks of each intervention.
  measure: L-citrulline levels
  time frame: 2 weeks of each intervention
  description: Serum levels of l-citrulline will be assessed before and after 2 weeks of each intervention.
  measure: L-ornithine levels
  time frame: 2 weeks of each intervention
  description: Serum levels of l-ornithine will be assessed before and after 2 weeks of each intervention.
  arm group label: L-Citrulline
  arm group type: Experimental
  description: L-Citrulline: 6 grams/day divided in 2 equal doses
  arm group label: Placebo
  arm group type: Placebo Comparator
  description: Microcrystalline cellulose: 8 capsules/day divided into 2 equal doses
  intervention type: Dietary Supplement
  intervention name: L-Citrulline
  description: 2 weeks of L-Citrulline supplementation (6 grams/day)
  arm group label: L-Citrulline
  intervention type: Dietary Supplement
  intervention name: Placebo
  description: 2 weeks of microcrystalline cellulose supplementation (8 capsules/day)
  arm group label: Placebo
  criteria: 
  gender: Female
  minimum age: 50 Years
  maximum age: 70 Years
  healthy volunteers: Accepts Healthy Volunteers
  last name: Arturo Figueroa
  role: Principal Investigator
  affiliation: Texas Tech University
  last name: Arturo Figueroa
  phone: 806-834-5587
  email: Arturo.Figueroa@ttu.edu
  facility: 
  status: Recruiting
  contact: 
  country: United States
  citation: Maharaj A, Fischer SM, Dillon KN, Kang Y, Martinez MA, Figueroa A. Acute Citrulline Blunts Aortic Systolic Pressure during Exercise and Sympathoactivation in Hypertensive Postmenopausal Women. Med Sci Sports Exerc. 2022 May 1;54(5):761-768. doi: 10.1249/MSS.0000000000002848. Epub 2022 Jan 3.
  PMID: 34974502
  citation: Maharaj A, Fischer SM, Dillon KN, Kang Y, Martinez MA, Figueroa A. Effects of L-Citrulline Supplementation on Endothelial Function and Blood Pressure in Hypertensive Postmenopausal Women. Nutrients. 2022 Oct 20;14(20):4396. doi: 10.3390/nu14204396.
  PMID: 36297080
  citation: Kang Y, Dillon KN, Martinez MA, Maharaj A, Fischer SM, Figueroa A. Combined L-Citrulline Supplementation and Slow Velocity Low-Intensity Resistance Training Improves Leg Endothelial Function, Lean Mass, and Strength in Hypertensive Postmenopausal Women. Nutrients. 2022 Dec 23;15(1):74. doi: 10.3390/nu15010074.
  PMID: 36615732
  citation: Figueroa A, Maharaj A, Kang Y, Dillon KN, Martinez MA, Morita M, Nogimura D, Fischer SM. Combined Citrulline and Glutathione Supplementation Improves Endothelial Function and Blood Pressure Reactivity in Postmenopausal Women. Nutrients. 2023 Mar 23;15(7):1557. doi: 10.3390/nu15071557.
  PMID: 37049398
  citation: Figueroa A, Alvarez-Alvarado S, Jaime SJ, Kalfon R. l-Citrulline supplementation attenuates blood pressure, wave reflection and arterial stiffness responses to metaboreflex and cold stress in overweight men. Br J Nutr. 2016 Jul;116(2):279-85. doi: 10.1017/S0007114516001811. Epub 2016 May 10.
  PMID: 27160957
  responsible party type: Principal Investigator
  investigator affiliation: Texas Tech University
  investigator full name: Arturo Figueroa
  investigator title: Arturo Figueroa, Principal Investigator
  mesh term: Hypertension
  sharing ipd: No